PFS and OS as a function of treatment in study population. Curves on the left represent all patients who received study drug (N = 29) and CIs. Curves on the right are subdivided between non–T-cell (n = 11) and T-cell patients (n = 18). (A) Median PFS is 3.7 months for all patients (95% CI, 1.4, 10.8) and 4.4 months for T-cell lymphoma patients (95% CI, 3.5) and for non–T-cell lymphoma is 1.8 months (95% CI, 1.2). (B) Median OS for all patients is 13.8 months (95% CI, 8.8 to not achieved [N/A]); for TCL patients is 12.4 months (95% CI, 8.1) and non–T-cell lymphoma 34 months (95% CI, 9.7). (C) Swimmer’s plot detailing the PFS of all T-cell lymphoma patients enrolled in the study. Start time denotes the first dose of study drugs. Stop time denotes progression of disease (POD), change in treatment (including transplant), or death.